Prevalence of microalbuminuria in non-diabetic hypertensive patients attended by Portuguese GPs

Revista Portuguesa de Cardiologia

Volumn 26, Issue 6, 2007, Pages 637-644

  Polónia, Jorge ^a   Carmona, José ^a   Mendes, Eduardo ^a   Pisco, Luís ^a  

^a NONE

Author keywords

Antihypertensive; Cardiovascular risk; Hypertension; Microalbuminuria; Renal function

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT;

ARTICLE; BRAIN HEMORRHAGE; CIGARETTE SMOKING; CONTROLLED STUDY; DEMOGRAPHY; DOCTOR PATIENT RELATION; GENERAL PRACTITIONER; HEALTH SURVEY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MICROALBUMINURIA; PREVALENCE; PROTEINURIA; QUESTIONNAIRE; TRANSIENT ISCHEMIC ATTACK; URINALYSIS;

ALBUMINURIA; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PORTUGAL; PREVALENCE;

EID: 34547215375     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31:673-689
2. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P. Irbesartan in patients in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with diabetes type 2. N Engl J Med 2001;345:870-878
3. Bigazzi R, Bianchi S, Campese V, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992;61:94-97
4. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al., HOPE study investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426
5. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782
6. Palatini P, Graniero GR, Mormino P et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory recording Venetia Study (HARVEST Study). Am J Hypertens 1996;9:334-341
7. Parving HH, Jensen HAE, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974;1:1190-1192
8. Pontremoli R, Sofia A, Ravera M et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC study. Microalbuminuria: a Genoa Investigation on Complications. Hypertension 1997;30:1135-1143
9. Patrick AW, Leslie PJ, Clarke BF, Frier BM. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis. Diabet Med 1990;7:902-908
10. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736-741
11. Rodicio L, Campo C, Ruilope LM. Microalbuminuria in essential hypertension. Kidney Inter, Suppl 1998; 68:S51-S54
12. Mimran A, Ribstein J, Du Cailar G. Microalbuminuria in essential hypertension. Curr Opin Nephrol Hypertens 1999;8:359-363
13. Mimran A, Ribstein J, Du Cailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 1994;23(pt2):1018-1021
14. Segura J, Ruilope M, Rodicio JL. Microalbuminuria. Clin Experim Hyper 2004;26(7-8):701-707
15. Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, Parodi A, Vettoretti S, Ratto E, Deferrari G. Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol 2005;16:S39-S41
16. Verdecchia P, Reboldi GP. Hypertension and microalbuminuria: the new detrimental duo. Blood pressure 2004;13:198-211
17. Reboldi G, Gentile G, Angeli F, Verdecchia P. Microalbuminuria and hypertension 2005;96(4):261-275
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003;21:1011-1053
19. Garçao J. A. and Cabrita J., 2002. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm Assoc (Wash). 2002 ; 42 (6): 858-64
20. Joint National Committee on Preventive Detection, Evaluation and treatment of High Blood Pressure. The sixth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Int Med 1997;157:2413-2446
21. Wachtell K, Palmieri V, Olsen MH et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reduction. Am Heart J 2002;143:319-326
22. Wachtell K, Olsen MH, Dahlof B et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002;20:405-412
23. De Alvaro F, Velasco O, Honorato J et al., on behalf of the KORAL HT Investigators. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan. Kidney Intern 2005; 67(93):S29-S34
24. World Health Organization-International Society of Hypertension; Guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens 1999;17:151-183
25. Mancia G, Grassi G. Joint National Committee VII and European Society of Hypertension/European Society of Cardiology guidelines for evaluating and treating hypertension: a two-way road? J Am Soc Nephrol 2005;16(1):S74-S77